TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01852669
Drug: Hydration
Normalized name: Eucerin Daily Hydration
DrugBank: Avobenzone (DB09495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydration of patient with 0.5L NaCl and 20mg frusemide IV
Study: NCT01121224
Drug: Blinded clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
Study: NCT01121224
Drug: Thienopyridine (open-label)
Normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
Study: NCT04035005
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
Study: NCT03574818
Drug: Necitumumab-Gemcitabine-Cisplatin
Normalized name: Necitumumab
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles.
Study: NCT03162120
Drug: Ranolazine plus Metoprolol Combination
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Study: NCT03162120
Drug: FlecainidE pluS Metoprolol Combination
Normalized name: metoprolol and thiazides, combinations
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Study: NCT03153319
Drug: Adalimumab Injection [Humira]
Normalized name: adalimumab Injection [Humira]
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigational Drug
Study: NCT00104598
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01018784
Drug: MORAb-009
Normalized name: Immunoglobulin G1, anti-(mesothelin) (human-mouse monoclonal MORAb-009 heavy chain), disulfide with human-mouse monoclonal MORAb-009 .Kappa.-chain, dimer
DrugBank: Amatuximab (DB12845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
Study: NCT02350764
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02350764
Drug: pilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00485797
Drug: Ritalin
Normalized name: Ritalin
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
Study: NCT00103350
Drug: TG100-115
Normalized name: TG100-115
DrugBank: TG100-115 (DB05552)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01929941
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
Study: NCT01929941
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
Study: NCT01502800
Drug: ARQ 761
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
Study: NCT02128685
Drug: Dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01502800
Drug: ARQ 761 Weekly Administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study: NCT01502800
Drug: Bi-Weekly Administration of ARQ 761
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study: NCT01502800
Drug: Two Consecutive Weeks Administration of ARQ 761 with one week of rest
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study: NCT00171080
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00171080
Drug: irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00359073
Drug: montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg everyday
Study: NCT00213993
Drug: antiperspirant
Normalized name: AXE Antiperspirant, Essence
DrugBank: Aluminum chlorohydrate (DB11573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiperspirant topically once daily to one foot
Study: NCT02743611
Drug: Rimiducid
Normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
Study: NCT01317108
Drug: CMF Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04444856
Drug: Eptacog alfa (activated)
Normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
Study: NCT00317031
Drug: Acamprosate or Naltrexone
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mg\&d 90 days
Study: NCT03390010
Drug: Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Study: NCT03390010
Drug: Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost
DrugBank: Carboprost (DB19356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Study: NCT00729469
Drug: Ospemifene 60 mg
Normalized name: ospemifene 60 MG
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
Study: NCT00952432
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine 200mg, 1/2 tablet, TID for 1 month
Study: NCT01302145
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet
Study: NCT03711240
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg iv day 1 every 2 weeks
Study: NCT03711240
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study: NCT03711240
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
Study: NCT03711240
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Study: NCT03862807
Drug: Patisiran
Normalized name: patisiran
DrugBank: Patisiran (DB14582)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patisiran was administered via IV infusion.
Study: NCT03673137
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
Study: NCT04362761
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT01771627
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01771627
Drug: nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02414165
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02414165
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01270802
Drug: Tenofovir/emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
Study: NCT01270802
Drug: Tenofovir/emtricitabine/efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued therapy with tenofovir/emtricitabine/efavirenz
Study: NCT01270802
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
Study: NCT03051620
Drug: Discontinue alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 136 patients with osteoporosis stopping treatment with alendronate.
Study: NCT04775602
Drug: 18F-PSMA
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
Study: NCT03217474
Drug: Ganciclovir (GCV)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
Study: NCT00330772
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00330772
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04734678
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg IV only once
Study: NCT04734678
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg/day IV for 2 doses 12-24 hours
Study: NCT01731431
Drug: Glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02914028
Drug: Tramadol and paracetamol
Normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
Study: NCT02872220
Drug: Sodium chloride [NaCl]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
Study: NCT01229462
Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Study: NCT01229462
Drug: brimonidine tartrate ophthalmic solution
Normalized name: Brimonidine Tartrate Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Study: NCT01229462
Drug: timolol ophthalmic solution
Normalized name: timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Study: NCT02141438
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
Study: NCT02052713
Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
Study: NCT02052713
Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
Study: NCT01915303
Drug: Pasireotide with or without cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
Study: NCT01332461
Drug: fluticasone propionate/salmeterol xinafoate combination
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients filling a prescription for fluticasone/salmeterol combination as index drug
Study: NCT00548184
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monoclonal Antibody
Study: NCT00548184
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal Antibody
Study: NCT00717236
Drug: Certolizumab pegol (CZP)
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
Study: NCT00416039
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
Study: NCT03366142
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
Study: NCT04285983
Drug: Trelagliptin
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Trelagliptin tablets
Study: NCT03692819
Drug: Amoxicillin 500 Mg
Normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
Study: NCT03692819
Drug: Lactobacillus reuteri Oral Drops
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
Study: NCT02875548
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
Study: NCT03911817
Drug: Midodrine
Normalized name: Midodrine
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
Study: NCT01728935
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil 300mg daily
Study: NCT04500561
Drug: YY-20394
Normalized name: Peptide YY
DrugBank: Peptide YY (3-36) (DB05004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
Study: NCT02410343
Drug: TV-1106
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
Study: NCT00005815
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005815
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02206100
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03587740
Drug: T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
Study: NCT04273763
Drug: Bromhexine Hydrochloride Tablets
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine Hydrochloride Tablets
Study: NCT04273763
Drug: Arbidol Hydrochloride Granules
Normalized name: colestipol hydrochloride Granule Product
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.